-
1
المؤلفون: Hanna, M.G., Badrising, U.A., Benveniste, O., Lloyd, T.E., Needham, M., Chinoy, H., Aoki, M., Machado, P.M., Liang, C., Reardon, K.A., Visser, M. de, Ascherman, D.P., Barohn, R.J., Dimachkie, M.M., Miller, J.A.L., Kissel, J.T., Oskarsson, B., Joyce, N.C., Bergh, P. van den, Baets, J., Bleecker, J.L. de, Karam, C., David, W.S., Mirabella, M., Nations, S.P., Jung, H.H., Pegoraro, E., Maggi, L., Rodolico, C., Filosto, M., Shaibani, A.I., Sivakumar, K., Goyal, N.A., Mori-Yoshimura, M., Yamashita, S., Suzuki, N., Katsuno, M., Murata, K., Nodera, H., Romano, C.D., Williams, V.S.L., Vissing, J., Auberson, L.Z., Wu, M., Vera, A. de, Papanicolaou, D.A., Amato, A.A., Nishino, I., RESILIENT Study Grp
المساهمون: Neurology, ANS - Neuroinfection & -inflammation, UCL - SSS/IONS/NEUR - Clinical Neuroscience, UCL - (SLuc) Service de neurologie, RESILIENT Study Grp
المصدر: Lancet neurology, 18(9), 834-844. Lancet Publishing Group
The Lancet. Neurology, Vol. 18, no. 9, p. 834-844 (2019)
The lancet neurology
The Lancet Neurology, 18(9), 834-844
Hanna, M G, Badrising, U A, Benveniste, O, Lloyd, T E, Needham, M, Chinoy, H, Aoki, M, Machado, P M, Liang, C, Reardon, K A, de Visser, M, Ascherman, D P, Barohn, R J, Dimachkie, M M, Miller, J A L, Kissel, J T, Oskarsson, B, Joyce, N C, Van den Bergh, P, Baets, J, De Bleecker, J L, Karam, C, David, W S, Mirabella, M, Nations, S P, Jung, H H, Pegoraro, E, Maggi, L, Rodolico, C, Filosto, M, Shaibani, A I, Sivakumar, K, Goyal, N A, Mori-Yoshimura, M, Yamashita, S, Suzuki, N, Katsuno, M, Murata, K, Nodera, H, Nishino, I, Romano, C D, Williams, V S L, Vissing, J, Auberson, L Z, Wu, M, de Vera, A, Papanicolaou, D A & Amato, A A 2019, ' Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT) : a randomised, double-blind, placebo-controlled phase 2b trial ', The Lancet Neurology, vol. 18, no. 9, pp. 834-844 . https://doi.org/10.1016/S1474-4422(19)30200-5مصطلحات موضوعية: Adult, Male, 0301 basic medicine, medicine.medical_specialty, Myostatin, Guidelines, Population, Guidelines, Antibodies, Monoclonal, Humanized, Placebo, Myositis, Inclusion Body, law.invention, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Randomized controlled trial, law, Internal medicine, medicine, Humans, education, Adverse effect, Bimagrumab, Aged, Aged, 80 and over, education.field_of_study, business.industry, Repeated measures design, Middle Aged, Myostatin, Settore MED/26 - NEUROLOGIA, Treatment Outcome, 030104 developmental biology, Blood chemistry, Tolerability, Female, Human medicine, Neurology (clinical), business, 030217 neurology & neurosurgery
وصف الملف: application/pdf
-
2دورية
المؤلفون: Bleecker, J.L. De, Meire, V.I., Declercq, W., Aken, E.H. Van
المصدر: Neuromuscular Disorders; 1999, Vol. 9 Issue: 4 p239-246, 8p